Overview of hepatocarcinogenesis focusing on cellular origins of liver cancer stem cells: a narrative review.

J Yeungnam Med Sci

Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Ilsan, Korea.

Published: November 2024

Hepatocellular carcinoma (HCC) accounts for 85% to 90% of primary liver cancers and generally has a poor prognosis. The hierarchical model, which posits that HCC originates from liver cancer stem cells (CSCs), is now widely accepted, as it is for other cancer types. As CSCs typically reside in the G0 phase of the cell cycle, they are resistant to conventional chemotherapy. Therefore, to effectively treat HCC, developing therapeutic strategies that target liver CSCs is essential. Clinically, HCCs exhibit a broad spectrum of pathological and clinical characteristics, ranging from well-differentiated to poorly differentiated forms, and from slow-growing tumors to aggressive ones with significant metastatic potential. Some patients with HCC also show features of cholangiocarcinoma. This HCC heterogeneity may arise from the diverse cellular origins of liver CSCs. This review explores the normal physiology of liver regeneration and provides a comprehensive overview of hepatocarcinogenesis, including cancer initiation, isolation of liver CSCs, molecular signaling pathways, and microRNAs. Additionally, the cellular origins of liver CSCs are reviewed, emphasizing hematopoietic and mesenchymal stem cells, along with the well-known hepatocytes and hepatic progenitor cells.

Download full-text PDF

Source
http://dx.doi.org/10.12701/jyms.2024.01088DOI Listing

Publication Analysis

Top Keywords

liver cscs
16
cellular origins
12
origins liver
12
stem cells
12
overview hepatocarcinogenesis
8
liver
8
liver cancer
8
cancer stem
8
cscs
6
hcc
5

Similar Publications

Background: Necroptosis, a recently identified mechanism of programmed cell death, exerts significant influence on various aspects of cancer biology, including tumor cell proliferation, stemness, metastasis, and immunosuppression. However, the role of necroptosis-related genes (NRGs) in Hepatocellular Carcinoma (HCC) remains elusive.

Methods: In this study, we assessed the mutation signature, copy number variation, and expression of 37 NRGs in HCC using the TCGA-LIHC dataset.

View Article and Find Full Text PDF

Overview of hepatocarcinogenesis focusing on cellular origins of liver cancer stem cells: a narrative review.

J Yeungnam Med Sci

November 2024

Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Ilsan, Korea.

Hepatocellular carcinoma (HCC) accounts for 85% to 90% of primary liver cancers and generally has a poor prognosis. The hierarchical model, which posits that HCC originates from liver cancer stem cells (CSCs), is now widely accepted, as it is for other cancer types. As CSCs typically reside in the G0 phase of the cell cycle, they are resistant to conventional chemotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • * New strategies are needed to enhance chemotherapy effectiveness while reducing side effects, focusing on substances like propolis and its flavonoids that may improve responses to treatment.
  • * Propolis appears to help by inhibiting nuclear factor kappa B (NF-κB) activation, modifying tumor-associated macrophages, and reducing factors that contribute to cancer cell survival, thus potentially overcoming chemoresistance.
View Article and Find Full Text PDF

Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma.

Oncol Rep

December 2024

Department of Biomolecular Sciences, School of Life Science, Pharmacy and Chemistry, Faculty of Health, Science, Social Care and Education, Kingston University London, Kingston upon Thames KT1 2EE, UK.

The aberrant expression of HER family members and cancer stem cells (CSCs) have been associated with tumour progression and resistance to therapy. At present, several HER inhibitors have been approved for the treatment of patients with a range of cancers but not for the treatment of patients with hepatocellular carcinoma (HCC). The present study investigated the co‑expression and prognostic significance of HER family members, type‑III deletion mutant EGFR (EGFRvIII), and the putative CSC biomarkers CD44 and epithelial cell adhesion molecule (EpCAM) in 43 patients with HCC.

View Article and Find Full Text PDF
Article Synopsis
  • * Targeting CSCs with specific drugs holds potential for curing HCC, as these cells are linked to the cancer's initiation, spread, and recurrence.
  • * Mitochondria are vital for CSC drug resistance due to their roles in metabolism and reactive oxygen species (ROS) dynamics; understanding mitochondrial functions could lead to new cancer therapies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!